This is the same 2-DAA regimen (ABT-450/ABT-267) for which ABVV/ENTA have GT4 approval in the EU and have a pending review for GT1b approval in Japan; however (unlike the EU and [proposed] Japanese labels), the FDA label includes use of ribavirin. ENTA receives a tiered double-digit royalty based on 45% (rather than 30%) of the gross sales.
GT4 represents about 6% of the US HCV market. The US brand name for the regimen is Technivie.
[An earlier version of this post said that the FDA label regimen did not include ribavirin.]
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.